semaglutide and multiple sclerosis The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Sclerosis: A Narrative Review MULTIPLE SCLEROSIS(MS) and its cousins,

With Semaglutide, the range is more like 1015%, though some people do better depending on their dose and routine

Risks associated with mass-produced compounded GLP-1s Although the FDA has declared that the supply shortage is resolved, some companies continue to mass produce compounded versions of GLP-1s, claiming that the drugs are personalized for patient needs by altering the method of delivery (e.g., gummy, injection, spray) or adding unnecessary and unproven ingredients like B12 and glycine

Preclinical data confirms that

However, disturbances such as FFA levels, increased de novo lipogenesis, impaired fatty acid oxidation, and reduced lipid export collectively contribute to disrupted hepatic lipid metabolism [39]

The case underscores a key issue clinicians are seeing more often: differentiating GLP-1 related gastrointestinal intolerance from cannabis hyperemesis syndrome, especially in medically complex patients

As more patients begin GLP-1 therapy, pharmacists play a critical role in helping them manage side effects, stay adherent, and achieve better outcomes